Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …

Rituximab (a chimeric anti-CD20 monoclonal antibody) is the first Food and Drug
Administration approved anti-tumor antibody. Immunotherapy by rituximab, especially in …

Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma …

Targeting the surface of malignant cells has evolved into a cornerstone in cancer therapy,
paradigmatically introduced by the success of humoral immunotherapy against CD20 in …

Background Treatment options for patients with relapsed or refractory lymphoma and
multiple myeloma are limited. CUDC-907 is an oral, first-in-class, small molecule that is …

We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of
therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb …

Abstract Purpose: Although R-CHOP–based immunochemotherapy cures significant
proportions of patients with aggressive B-cell lymphoma, tumor cell susceptibility to …

Ligand-targeted therapeutics have increased in prominence because of their potential for
improved potency and reduced toxicity. However, with the advent of personalized medicine …

Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-
cell-derived haematological malignancies. Rituximab, in combination with chemotherapy …

Recovery rates for B-cell Non-Hodgkin's Lymphoma (NHL) are up to 70% with current
standard-of-care treatments including rituximab (chimeric anti-CD20 monoclonal antibody) …